Debra A Bell

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Origins and molecular pathology of ovarian cancer
    Debra A Bell
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Mod Pathol 18:S19-32. 2005
  2. ncbi request reprint Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer
    Zhenfeng Duan
    Division of Hematology Oncology, Department of Pathology, and Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:5055-63. 2006
  3. ncbi request reprint Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma
    Sarah E Rollins
    James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Surg Pathol 30:457-62. 2006
  4. ncbi request reprint Psammoma bodies in cervicovaginal cytology specimens: a clinicopathological analysis of 31 cases
    Joseph Misdraji
    Department of Pathology and Cytopathology Laboratory, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Gynecol Oncol 103:238-46. 2006
  5. ncbi request reprint Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas
    Colleen M Feltmate
    Department of Obstetrics, Gynecology, and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 11:7651-7. 2005
  6. ncbi request reprint Current issues in the pathology of ovarian cancer
    Joseph T Rabban
    Gillette Center in Women s Cancer Pathology and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Reprod Med 50:467-74. 2005
  7. ncbi request reprint Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives
    Debra A Bell
    Department of Pathology, Massachusetts General Hospital, Boston 02114 2696, USA
    Hum Pathol 35:934-48. 2004
  8. ncbi request reprint Superficial endometriosis of the cervix: A source of abnormal glandular cells on cervicovaginal smears
    Wanda M Szyfelbein
    James Homer Wright Pathology Laboratories of the Massachusetts General Hospital, Department of Pathology, Harvard Medical School, Boston, MA 02114, USA
    Diagn Cytopathol 30:88-91. 2004
  9. ncbi request reprint Classification of benign endometrial glandular cells in cervical smears from postmenopausal women
    Edi Brogi
    Department of Pathology, Cytology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 96:60-6. 2002
  10. ncbi request reprint Borderline ovarian tumors: key points and workshop summary
    Steven G Silverberg
    Department of Pathology, University of Maryland School of Medicine, Baltimore 21201, USA
    Hum Pathol 35:910-7. 2004

Detail Information

Publications12

  1. ncbi request reprint Origins and molecular pathology of ovarian cancer
    Debra A Bell
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Mod Pathol 18:S19-32. 2005
    ....
  2. ncbi request reprint Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer
    Zhenfeng Duan
    Division of Hematology Oncology, Department of Pathology, and Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:5055-63. 2006
    ..To further clarify the significance of Stat3 activation in ovarian cancer, here we investigated the Stat3 expression and activation in ovarian cancer and ovarian cancer multidrug resistance cell lines...
  3. ncbi request reprint Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma
    Sarah E Rollins
    James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Surg Pathol 30:457-62. 2006
    ....
  4. ncbi request reprint Psammoma bodies in cervicovaginal cytology specimens: a clinicopathological analysis of 31 cases
    Joseph Misdraji
    Department of Pathology and Cytopathology Laboratory, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Gynecol Oncol 103:238-46. 2006
    ..Psammoma bodies in cervicovaginal cytology specimens are associated with malignant and benign conditions. Few studies have evaluated which features distinguish patients with underlying malignancy from those with benign conditions...
  5. ncbi request reprint Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas
    Colleen M Feltmate
    Department of Obstetrics, Gynecology, and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 11:7651-7. 2005
    ..The purpose of this study is to identify molecular biomarkers for mucinous ovarian adenocarcinoma and compare them with those of appendiceal origin...
  6. ncbi request reprint Current issues in the pathology of ovarian cancer
    Joseph T Rabban
    Gillette Center in Women s Cancer Pathology and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Reprod Med 50:467-74. 2005
    ..Special processing of the pathologic specimens is required to detect early and minimal neoplasia in this setting. These current issues in the pathology of ovarian carcinoma and their clinical significance form the basis of this review...
  7. ncbi request reprint Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives
    Debra A Bell
    Department of Pathology, Massachusetts General Hospital, Boston 02114 2696, USA
    Hum Pathol 35:934-48. 2004
    ....
  8. ncbi request reprint Superficial endometriosis of the cervix: A source of abnormal glandular cells on cervicovaginal smears
    Wanda M Szyfelbein
    James Homer Wright Pathology Laboratories of the Massachusetts General Hospital, Department of Pathology, Harvard Medical School, Boston, MA 02114, USA
    Diagn Cytopathol 30:88-91. 2004
    ..However, the cytologic features of endometriosis show sufficient overlap with those of precancerous and cancerous glandular lesions that many of these cases will continue to be diagnosed as "atypical glandular cells."..
  9. ncbi request reprint Classification of benign endometrial glandular cells in cervical smears from postmenopausal women
    Edi Brogi
    Department of Pathology, Cytology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 96:60-6. 2002
    ..However, PMP women on hormone replacement therapy (HRT) sometimes may experience endometrial shedding. The significance of such a finding has not been investigated in detail...
  10. ncbi request reprint Borderline ovarian tumors: key points and workshop summary
    Steven G Silverberg
    Department of Pathology, University of Maryland School of Medicine, Baltimore 21201, USA
    Hum Pathol 35:910-7. 2004
    ....
  11. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2004. A 52-year-old woman with postmenopausal bleeding and a cystic ovarian mass
    Richard T Penson
    Cancer Center, Department of Medicine, Division of Hematology Oncology, Massachusetts General Hospital, USA
    N Engl J Med 351:2531-8. 2004
  12. ncbi request reprint Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer
    Jeremy R Chien
    Department of Experimental Pathology, Mayo Clinic, Rochester, Minnesota, USA
    J Cell Biochem 102:1117-29. 2007
    ..Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance...